Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Piperaquine microcapsules and compositions containing them

a technology of piperaquine and compositions, applied in the direction of coatings, pill delivery, organic active ingredients, etc., can solve the problems of difficult to medicate children, tablets or capsules, and dosage forms, so as to prevent and minimize the degradation of further highly reactive agents, the effect of reducing the discoloration upon light exposur

Inactive Publication Date: 2014-10-30
ADARE PHARM SRL
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about a new way to make medicine that tastes better and is more stable. The medicine contains microcapsules that have been made to mask the taste and prevent the medicine from changing color when exposed to light. The patent also explains how to make a stable combination of the microcapsules with other drugs that can be sensitive or reactive. This can be useful for making medicine that is more effective and easier to use.

Problems solved by technology

However, such dosage forms have several disadvantages.
In particular, it is difficult for some elderly persons to swallow tablets or capsules or to medicate children who are unable or unwilling to swallow tablets or capsules.
This leads to poor or non-compliance with the treatment, and thus has a negative impact on the efficacy of the treatment.
However, simple addition of a taste-masking agent such as a flavoring agent or sweetener is frequently not useful by itself, unless the drug to be taste-masked is not particularly bitter.
Formulating piperaquine or piperaquine phosphate in their different forms is complicated by its bitter taste.
Furthermore, PQP may induce chemical reactions on chemically reactive agents; instability and decomposition or degradation of chemically sensitive active agent such as dihydroartemisinin may occur when this agent is used in combination with PQP (Chem. Med. Chem., 2007, 1448-1463).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Piperaquine microcapsules and compositions containing them
  • Piperaquine microcapsules and compositions containing them
  • Piperaquine microcapsules and compositions containing them

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018]All documents cited herein are incorporated by reference for all purposes.

[0019]As used herein, the term “microcapsules” refers to a drug core coated with polymeric material, that is the polymeric material forms a layer around the drug core.

[0020]The term “coacervated microcapsules” refers to a drug core coated with polymeric material using the coacervation method.

[0021]“Microencapsulation conducted by phase separation” and “coacervation” mean an encapsulation process in which the drug is dispersed in a solution containing a coating polymeric material, and procedures are then followed which result in deposition of the coating on the drug core, thus preparing “coacervated microcapsules”.

[0022]As used herein, the term “coating weight” or “coating level” refers to the dry weight of the polymeric material divided by the weight of the entire microcapsule, multiplied by 100. For example, a coating weight of 15% w / w means that for the given microcapsule, the coating constitutes 15% o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a microcapsule pharmaceutical composition of at least a bisquinoline drug. said microcapsule comprises a drug core of a pharmaceutically effective amount of a bisquinoline drug and a polymeric coating over the core. This microcapsule pharmaceutical composition has desirable pharmaceutical properties, including taste masking effect and a high stability.

Description

REFERENCE TO PRIOR APPLICATION[0001]This application claims the benefit of U.S. Provisional Application No. 61 / 804,448, filed Mar. 22, 2013, the disclosure of which is incorporated by reference herein in its entirety.BACKGROUND[0002]The most widely used dosage forms for oral administration include tablets and capsules. However, such dosage forms have several disadvantages. For example, it is estimated that 50% of the population have problems swallowing tablets. In particular, it is difficult for some elderly persons to swallow tablets or capsules or to medicate children who are unable or unwilling to swallow tablets or capsules. This leads to poor or non-compliance with the treatment, and thus has a negative impact on the efficacy of the treatment. The bitter taste of many actives precludes the medication from being easily sprinkled onto food, a commonly used method of administering medications to elderly and children.[0003]A number of methods are known for masking the taste of drug...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/50A61K31/496A61K9/28A61K9/00A61K9/48
CPCA61K9/5047A61K9/0056A61K9/4891A61K9/009A61K31/496A61K9/0004A61K9/5089A61K9/2866A61K45/06A61K9/5026A61P33/06Y02A50/30A61K2300/00
Inventor STOLLBERG, CHRISTIANBIANCHI, GIANCARLAFABIANI, FLAVIOBOLTRI, LUIGI
Owner ADARE PHARM SRL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products